Evidence map›Paper›PMID 26276390›Full record

ArticleThe Journal of biological chemistry2015

The IVVY Motif and Tumor Necrosis Factor Receptor-associated Factor (TRAF) Sites in the Cytoplasmic Domain of the Receptor Activator of Nuclear Factor κB (RANK) Cooperate to Induce Osteoclastogenesis.

Joel Jules, Shunqing Wang, Zhenqi Shi, Jianzhong Liu, Shi Wei, Xu Feng

Open access · hybridAbstract read
In one paragraph

Article in The Journal of biological chemistry, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.

0numbers the graph read from it
0cells of the map it votes in
15citing papers in PubMed
1.5field-weighted citation impact, top 18% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

15 citing papers in PubMed, 22 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
  4. Article
  5. Article
  6. Article
  7. Review
  8. Article
  9. Specific RANK Cytoplasmic Motifs Drive Osteoclastogenesis.Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research · 2019
    Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 2 countries.

Joel JulesFrom the Department of Pathology, University of Alabama at Birmingham, Birmingham, Alabama 35294 and.
Shunqing WangFrom the Department of Pathology, University of Alabama at Birmingham, Birmingham, Alabama 35294 and the Department of Hematology, Guangzhou First People's Hospital, Guangzhou Medical University, Guangzhou, Guangdong 510180, China.
Zhenqi ShiFrom the Department of Pathology, University of Alabama at Birmingham, Birmingham, Alabama 35294 and.
Jianzhong LiuFrom the Department of Pathology, University of Alabama at Birmingham, Birmingham, Alabama 35294 and.
Shi WeiFrom the Department of Pathology, University of Alabama at Birmingham, Birmingham, Alabama 35294 and.
Xu FengFrom the Department of Pathology, University of Alabama at Birmingham, Birmingham, Alabama 35294 and xufeng@uab.edu.
University of Alabama at Birmingham · USGuangzhou Medical University · CN

Funding

ROS Modulation of Innate and Adaptive Immunity in RAP30AR048311 · NIAMS · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI MOUNTZ, JOHN D · 2001 to 2017
$9.5M
RANK Signaling in Osteoclast Differentiation &FunctionR01AR047830 · NIAMS · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI FENG, XU · 2001 to 2016
$4.7M
NIAMS NIH HHS AR47830NIAMS NIH HHS P30 AR048311NIAMS NIH HHS R01 AR047830
6 · The paper itself

Abstract

Receptor activator of NF-κB (RANK) activation by RANK ligand (RANKL) mediates osteoclastogenesis by recruiting TNF receptor-associated factors (TRAFs) via three cytoplasmic motifs (motif 1, PFQEP(369-373); motif 2, PVQEET(559-564); and motif 3, PVQEQG(604-609)) to activate the NF-κB and MAPK signaling pathways. RANK also has a TRAF-independent motif (IVVY(535-538)), which is dispensable for the activation of TRAF-induced signaling pathways but essential for osteoclast lineage commitment by inducing the expression of nuclear factor of activated T-cells c1 (NFATc1) to regulate osteoclast gene expression. Notably, TNF/IL-1-mediated osteoclastogenesis requires RANK ligand assistance, and the IVVY motif is also critical for TNF/IL-1-mediated osteoclastogenesis by rendering osteoclast genes responsive to these two cytokines. Here we show that the two types of RANK cytoplasmic motifs have to be on the same RANK molecule to mediate osteoclastogenesis, suggesting a functional cooperation between them. Subsequent osteoclastogenesis assays with TNF or IL-1 revealed that, although all three TRAF motifs play roles in TNF/IL-1-mediated osteoclastogenesis, motifs 2 and 3 are more potent than motif 1. Accordingly, inactivation of motifs 2 and 3 blocksTNF/IL-1-mediated osteoclastogenesis. Mechanistically, double mutation of motifs 2 and 3, similar to inactivation of the IVVY motif, abrogates the expression of nuclear factor of activated T-cells c1 and osteoclast genes in assays reflecting RANK-initiated and TNF/IL-1-mediated osteoclastogenesis. In contrast, double inactivation of motifs 2 and 3 did not affect the ability of RANK to activate the NF-κB and MAPK signaling pathways. Collectively, these results indicate that the RANK IVVY motif cooperates with the TRAF-binding motifs to promote osteoclastogenesis, which provides novel insights into the molecular mechanism of RANK signaling in osteoclastogenesis.

Indexed as

Amino Acid MotifsAmino Acid SubstitutionAnimalsCell DifferentiationHumansInterleukin-1MAP Kinase Signaling SystemMiceMutation, MissenseNFATC Transcription FactorsNF-kappa BOsteoclastsReceptor Activator of Nuclear Factor-kappa BTumor Necrosis Factor-alphaInterleukin-1NFATC1 protein, humanNfatc1 protein, mouseNFATC Transcription FactorsNF-kappa BReceptor Activator of Nuclear Factor-kappa BTNF protein, humanTNFRSF11A protein, humanTnfrsf11a protein, mouseTumor Necrosis Factor-alphacell signalingIL-1IVVY motifosteoclastRANKRANKLTNFTNF receptor-associated factor (TRAF)

Identifiers

PMID26276390
PMCPMC4583028
OpenAlexW1861887592

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.